---
title: "Dianthus Therapeutics Chief Accounting Officer Edward Carr disposes of shares for $2.01 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299486586.md"
description: "Dianthus Therapeutics Chief Accounting Officer Edward Carr exercised options for 20,000 shares at $17.88 and sold them on September 17, 2026, for approximately $2.01 million. Following these transactions, his direct common stock holdings fell to zero, though he retains beneficial ownership of 43,818 stock options."
datetime: "2026-09-18T20:37:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299486586.md)
  - [en](https://longbridge.com/en/news/299486586.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299486586.md)
generator: "portal-rs"
---

# Dianthus Therapeutics Chief Accounting Officer Edward Carr disposes of shares for $2.01 million

-   Dianthus Therapeutics reported Chief Accounting Officer Edward Carr exercised stock options for 20,000 shares at USD 17.88 on Sep. 17, 2026. \* Carr sold 20,000 shares the same day at weighted-average prices from USD 100.43 to USD 104.39. \* His directly held common stock position fell to zero following the transactions. \* He reported beneficial ownership of 43,818 stock options after the exercise. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001273351-26-000006), on September 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [DNTH.US](https://longbridge.com/en/quote/DNTH.US.md)

## Related News & Research

- [Dianthus Therapeutics to present Phase 3 CAPTIVATE interim analysis of claseprubart in CIDP at 2026 AANEM meeting](https://longbridge.com/en/news/300432141.md)
- [Dianthus Therapeutics director Simon Read disposes of common shares worth $326,148.9](https://longbridge.com/en/news/296405573.md)
- [Microsoft Could Be SpaceX's Next Big AI Customer: Bernstein Sees AI Revenue Surging Nearly 500%](https://longbridge.com/en/news/300953883.md)
- [Microsoft's blazing stock comeback isn't even close to being over, analyst says](https://longbridge.com/en/news/300955443.md)
- [Western Digital vs. Sandisk: The Better Way to Play the Hard-Drive Side of the AI Storage Boom](https://longbridge.com/en/news/300870855.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**